Bausch Health's (BHC) Q4 results on Feb. 19 will be mainly eyed by investors for the company's 2025 guidance, a potential full separation of Bausch + Lomb (BLCO), and upcoming debt maturities in Q4 this year, RBC Capital Markets said Thursday.
RBC said it expects Bausch Health to post Q4 revenue of $2.56 billion, above the FactSet consensus of $2.52 billion, and adjusted EBITDA of $918.8 million, below the FactSet consensus of $939 million.
For 2025, RBC expects Bausch Health to deliver revenue of $10.01 billion, above consensus at $9.9 billion, and adjusted EBITDA of $3.42 billion, in line with consensus forecasts.
Meanwhile, the investment firm said it trimmed Bausch Health's price target to $10 from $11 as it's decreasing the Bausch + Lomb sale scenario weighting to 60% from 75% after a media report saying that Blackstone (BX) will likely drop out of a consortium with TPG (TPG) to take out the eye care company.
A potential sale of Bausch + Lomb would result in about $6.5 billion to $7.7 billion in proceeds to Bausch Health, RBC said.
The investment firm has a sector perform rating on Bausch Health.
Price: 7.46, Change: -0.01, Percent Change: -0.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。